CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2022

Mar 29, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr George Matcham
Date of Last Notice:	14 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevantinterest.		Held via broker nominee account.
Date of change		25 March 2022
No. of securities held prior to change				Options 2,750,000 - 2,750,000
			Shares	Options
		Direct	-	2,750,000
		Indirect	500,000	-
		Total	500,000	2,750,000
Class		a) Fully Paid Ordinary Shares b) Listed Options (ASX: CHMO)
Number acquired				Options - b) 158,730 158,730
			Shares	Options
		Direct	-	-
		Indirect	a) 158,730	b) 158,730
		Total	158,730	158,730

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	Number	dispose	d
									Shares	Options
							Direct		-	-
							Indirect		-	-
							Total		-	-
	Value/C Nt	onsidera	tion				a) $0.17 pe		r share. ‘	’
	oe: If consider valuation	ation is n	on-cash, provid	e details and estimate	d		b) Non-cas		h, see nature of	change below.
	No. of se	curities	held after ch	ange
									Shares	Options
							Direct		-	2,750,000
							Idit		658730	15873
							nrec		,	,
							Total		658,730	2,908,730
	Nature Example: on-market f riti	of chang trade, off- ndr di	e market trade, e idnd rint	xercise of options, issu nt ln rtiiti	e		a & b) Part (with free a February 2		icipation in Enti ttaching options 022.	tlement Offer ) announced 21
	o secu inbuy-bac	s ue k	ve eves	e pa, pacpao
	rt 2 – te: In the c tr” h	Change ase of a c ld b di	of director ompany, interes ld in thi	’s interests in c ts which come within rt	ontracts paragraph (ii) of				the definition of “n	otifiable interest of a

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relationtowhichtheinteresthas changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was N/A provided, on what date was this provided?

==> picture [38 x 24] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3